RECELL Successful Pivotal Trial Data Presented at ABA Day 3

Valencia, Calif., USA, and Melbourne, Australia, 13 April 2018 — AVITA Medical (ASX: AVH, OTCQX:
AVMXY) today announced that its pivotal, controlled clinical trial in the treatment of deep full-thickness
(third-degree) burns with the RECELL® Autologous Cell Harvesting Device achieved its co-primary endpoints,
demonstrating a statistically significant reduction in donor skin requirements versus standard of care while
achieving comparable definitive wound closure. The results were presented at the American Burn
Association (ABA) 50th Annual Meeting in Chicago by James H. Holmes, IV, MD, FACS, Wake Forest Baptist
Medical Center, Winston-Salem, North Carolina.
“Treatment with the RECELL Device achieved comparable healing, long-term scar and patient satisfaction
outcomes using significantly less donor skin with no safety concerns,” said Dr. Holmes. “I have had the
opportunity to evaluate RECELL through several clinical trials and the FDA-approved Compassionate Use
Program. I believe that the RECELL Device provides the opportunity to improve care for patients with severe
burns.”
The RECELL Device is an investigational medical device in the U.S. that is designed to enable medical
professionals to produce, at the point-of-care, a REGENERATIVE EPIDERMAL SUSPENSION™ (RES™) using a
small sample of the patient’s own skin. The autologous suspension contains cells necessary to regenerate
epidermis and provides a new way to achieve permanent closure in burns and other wounds while reducing
the amount of skin harvested at the time of surgery. Reduction in donor-site skin requirements has
important benefits from both clinical and health economic perspectives.
The presentation by Dr. Holmes, “Demonstration of the Safety and Effectiveness of Autologous Skin Cell
Suspension Combined with Meshed Skin Grafts for the Reduction of Donor Area in the Treatment of Acute
Burns,” described the outcomes from the controlled clinical trial conducted at seven U.S. burn centers.
During the pivotal trial, the patient donor skin required to be harvested to treat burn sites with the RECELL
Device was 32 percent less than the amount harvested to treat burn sites with the standard of care
(p<0.001). Despite the statistically significant reduction in donor skin required to treat with the RECELL
Device, burn sites treated with the RECELL Device achieved definitive closure comparable to the burn sites
treated with standard of care. At eight weeks post treatment, 92 percent of the burn sites treated with
RECELL achieved complete healing versus 85 percent for the sites treated with the standard of care,
demonstrating non-inferiority. Use of RECELL was safe and well tolerated with no treatment-related adverse
events considered device related.
The pivotal trial evaluated 30 patients ranging in age from nine to 68 years old with thermal, mixed-
thickness burns, including full-thickness burns, covering five percent to 46 percent of their total body
surface area. Patients served as their own control, and two comparable burn sites were selected for
comparative testing on each patient. One burn site was treated with the standard treatment, meshed
autograft, while the other was treated with the combination of the RECELL Device and more widely meshed
autografted (for example, if a 2:1 meshed autograft was used to treat the control burn site, then a 3:1
meshed autograft was used to treat the RECELL site). The co-primary endpoints of the pivotal trial were
reduction in donor skin requirements and non-inferiority in complete wound closure.
The Biomedical Advanced Research and Development Authority (BARDA), under the Assistant Secretary for
Preparedness and Response, within the US Department of Health and Human Services has provided funding
under Contract No. HHSO100201500028C to support the development of RECELL by AVITA Medical,
including the Compassionate Use program included in the presentation today.
###
ABOUT AVITA MEDICAL LIMITED
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet
medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and
proprietary collection and application technology provides innovative treatment solutions derived from the
regenerative properties of a patient’s own skin. Our medical devices work by preparing a REGENERATIVE
EPITHELIAL SUSPENSIONTM, an autologous suspension comprised of the patient’s own skin cells and wound
healing factors that are necessary to regenerate natural healthy skin. This autologous suspension is then
sprayed onto the areas of the patient to be treated.
In the United States, the RECELL Device is an investigational device limited by federal law to investigational
use. In September 2017, AVITA Medical submitted to the U.S. Food and Drug Administration (FDA) a
PreMarket Approval (PMA) application for RECELL for the treatment of burn injuries.
In all countries outside of Europe, our portfolio is marketed under the RECELL Device brand to promote skin
healing in a wide range of applications including burns, chronic wounds and aesthetics. RECELL Device is TGAregistered
in Australia, and CFDA-cleared in China.
In Europe, our portfolio of medical device products received CE-mark approval as three tailored product
presentations, with three individual brand names. RECELL Device is designed for the treatment of burns and
plastic reconstructive procedures; REGENERCELL™ Autologous Cell Harvesting Device has been formulated
for chronic wounds including leg and foot ulcers; and RENOVACELL™ Autologous Cell Harvesting Device is
tailored for aesthetic applications including the restoration of pigmentation.
To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This letter includes forward-looking statements. These forward-looking statements generally can be identified by the use
of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,”
“forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and
the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning,
among other things, our ongoing clinical trials and product development activities, regulatory approval of our products,
the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial
goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forwardlooking
statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others,
the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure
to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability
claims; risks associated with international operations and expansion; and other business effects, including the effects of
industry, economic or political conditions outside of the company’s control. Investors should not place considerable
reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly
available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter
speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.
FOR FURTHER INFORMATION:
OUS Media
Monsoon Communications
Sarah Kemter
Phone: +61 (0)3 9620 3333
Mobile: +61 (0)407 162 530
sarahk@monsoon.com.au
US Media
Syneos Health Public Relations
David Polk
Phone: +1 (310) 309 1029
Mobile +1 (805) 428 5775
david.polk@syneoshealth.com
Investors:
Westwicke Partners
Caroline Corner
Phone +1 (415) 202-5678
caroline.corner@westwicke.com
AVITA Medical Ltd
Dale A. Sander
Chief Financial Officer
Phone +1 (858) 663-6993
dsander@avitamedical.co